Publications

1.      Jennifer R Donnan, Karissa Johnston, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Mehdi Najafzadeh, Hai Nguyen, John-Michael Gamble.  Capturing Patient Preferences towards Benefits and Risks of Second-line Diabetes Therapies: A Discrete Choice Experiment. Canadian Journal of Diabetes. Accepted April 2019.  

 

2.      Jennifer R. Donnan, Catherine Grandy, Eugene Chibrikov, Carlo A. Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen, John-Michael Gamble. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: A systematic review and meta-analysis. BMJ Open. Accepted November 2018.

 

3.      John-Michael Gamble, Jennifer R. Donnan, Eugene Chibrikov, Laurie K. Twells, William K. Midodzi, Sumit R. Majumdar.Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Scientific Reports. Accepted October 2018.

 

4.      Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen, John-Michael Gamble. Dose Response of Sodium Glucose Co-Transporter-2 Inhibitors on Urinary Tract Infections: A Systematic Review and Network Meta-Analysis . CMAJ Open. Accepted October 2018.

 

5.        John-Michael Gamble, Jennifer R. Donnan, Eugene Chibrikov, Laurie K. Twells, William K. Midodzi, Sumit R. Majumdar. (2018). The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study. Diabetes Research and Clinical Practice. 136: 159-167.

 

6.        Catherine Anne Grandy, Jennifer R Donnan, Justin T Peddle, Kristen Romme, Satpyul Kim, John-Michael Gamble. (2018). A Systematic Assessment of the Availability and Clinical Drug Information Coverage of Machine-Readable Clinical Drug Data Sources for Building Knowledge Translation Products. Journal of the American Medical Informatics Association. (link to e-pub: https://academic.oup.com/jamia/advance-article-abstract/doi/10.1093/jamia/ocy074/5048777)

7.        Jennifer R Donnan. Testosterone deficiency syndrome: A look at treatments, adverse effects and therapeutic controversies. Pharmacy Practice + Business. December 2017.

 

8.        Daniel Krewski, Caroline Barakat-Haddad, Jennifer Donnan, Rosemary Martino, Tamara Pringsheim, Helen Tremlett, Pascal van Lieshout, Stephanie J Walsh , Nicholas J. Birkett, James Gomes, Julian Little, Hamilton Candundo, Ting-Kuang Chao, Kayla Collins, James A.G. Crispo, Tom Duggan, Reem El Sherif, Nawal Farhat, Yannick Fortin, Janet Gaskin, Pallavi Gupta, Mona Hersi, Wing Hoi Poon, Jing Hu, Brittany Irvine, Shayesteh Jahanfar, Don MacDonald Kyla McKay, Andrea Morrissey, Pauline Quach, Sabina Shin, Lindsey Sikora, Stacey Tkachuk, Mohamed K. Taher, Ming-Dong Wang, Shalu Darshan, Neil R Cashman. (2017). Determinants of Neurological Disease: Synthesis of Systematic Reviews. Neurotoxicology. 61: 266-289.

 

9.        Waseem Abu-Ashour, Laurie Twells, James Valcour, Amy Randell, Jennifer Donnan, Patricia Howse, John-Michael Gamble. (2017). The Association Between Diabetes Mellitus and Incident Infections: A Systematic Review And Meta-Analysis Of Observational Studies. BMJ Open Diabetes Research & Care. 2017;5:e000336.

 

10.    Donnan J, Walsh S, Sikora L, Morrissey A, Collins K, MacDonald D. (2017). A Systematic Review of the Risks Factors Associated with the Onset and Natural Progression of Spina Bifida. NeuroToxicology. 2017 Jul;61:20-31.

 

11.    Donnan J, Walsh S, Fortin Y, Gaskin J, Sikora L, Morrissey A, Collins K, MacDonald D. (2017). Factors Associated with the Onset and Progression of Neurotrauma: A Systematic Review of Systematic Reviews and Meta-Analyses. NeuroToxicology. 2017 Jul;61:233. 

 

12.    Walsh S, Donnan J, Sikora L, Morrissey A, Bowen S, Collins K, MacDonald D. (2017). A Systematic Review of the Risks Factors Associated with the Onset and Natural Progression of Hydrocephalus. NeuroToxicology. 2017 Jul;61:33-45.

 

13.    Walsh S, Donnan J, Fortin Y, Sikora L, Morrissey A, Collins K, MacDonald D. (2017). A Systematic Review of the RisksFactors Associated with the Onset and Natural Progression of Epilepsy. NeuroToxicology. (2017) Jul;61:64-77.

 

14.    Edwards S, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, Laing K, Whelan M, MacKinnon N. (2014). Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. Journal of Pharmacy Practice. 27(1): 46-52.

 

15.    Donnan J, Faseruk A. (2014). The Financial Implication of Using Decision Tree Analysis for Publicly Funded Health Care Screening in Canada. Journal of Modern Accounting and Auditing. 10(3): 344-355.

 

16.    Donnan J, Ungar W, Mathews M, Rahman P. (2011). Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Therapeutic Drug Monitoring. 33(2): 192-199.

17.    Donnan J, Ungar W., Mathews M, Hancock-Howard R, Rahman P. (2011). A Cost Effectiveness Analysis of Thiopurine Methyltransferase Testing For Guiding 6-Mercaptopurine Dosing In Children With Acute Lymphoblastic Leukemia. Pediatric Blood & Cancer. 57(2): 231-239.

 

Knowledge Translation: A more detailed report was published on the Technology Assessment at Sick Kids (TASK) website (https://www.sickkids.ca/pdfs/Research/TASK/thiopurin/33872-TPMT-highlights.pdf) to support broader uptake from clinicians and decision makers.

 

18.    Sikdar KC, Alaghehbandan R, MacDonald D, Barrett B, Collins KD, Donnan J, Gadag V. (2010). Adverse drug events in adult patients leading to emergency department visits. Annals of pharmacotherapy. 44(4): 641-649.

 

19.    Loder J, Lamoure J, Northcott S. (2006). Doctor, I don’t feel very well. The Canadian Journal of Diagnosis. 23(12): 35-37.

 

20.    Donnan J, Ledger S. (2006). An update on the treatment and management of diabetic peripheral neuropathy. CANNT Journal. 16(4): 32-38.

Presentations

1.      Laurie Twells, Jennifer Donnan, Alicia Taylor, Chelsey McPhee. Patients are a Virtue: Adding Lived Experience to your Research Team (Workshop). Diabetes Canada Summit 2019. 

 

2.      Jennifer Donnan, Kristin Walsh, Tanis Adey, Zhiwei Gao, Hai Nguyen, Alicia Taylor, David Pace, Jennifer Deon, Laurie Twells. Patient preferences towards characteristics to be used in prioritizing patients for bariatric surgery: A Discrete Choice Experiment. Diabetes Canada Summit 2019. 

 

3.      Jennifer Donnan, Kristin Walsh, Tanis Adey, Zhiwei Gao, Hai Nguyen, Alicia Taylor, David Pace, Jennifer Deon, Laurie Twells. Patient perceptions on characteristics for guiding prioritization of obese individuals for bariatric surgery. Diabetes Canada Summit 2019. 

 

4.      Donnan J. Patient Oriented Research: Experience in Diabetes and Obesity. SPOR Evidence Alliance Annual General Meeting. Toronto, Ontario, Canada (November 2018).

 

5.      Donnan J, Johnston K, Chibrikov E, Marra CA, Aubrey-Bassler K, Najafzadeh M, Nguyen H, Gamble JM.   (2018). Patient preferences among individuals with type 2 diabetes for attributes of diabetes medications: A Discrete Choice Experiment. Canadian Association for Population Therapeutics, Toronto, Ontario, Canada (October, 2018)

 

6.      Donnan J, Johnston K, Chibrikov E, Marra CA, Aubrey-Bassler K, Najafzadeh M, Nguyen H, Gamble JM.   (2018). Patient preferences among individuals with type 2 diabetes for attributes of diabetes medications: A Discrete Choice Experiment. Diabetes Canada, Halifax, Nova Soctia, Canada (October, 2018)

 

7.      Donnan J, Johnston K, Chibrikov E, Marra CA, Aubrey-Bassler K, Najafzadeh M, Nguyen H, Gamble JM.   (2018). Patient preferences among individuals with type 2 diabetes for attributes of diabetes medications: A Discrete Choice Experiment. PriFor, St. John’s, Newfoundland, Canada

 

8.      Donnan J, Johnston K, Chibrikov E, Marra CA, Aubrey-Bassler K, Najafzadeh M, Nguyen H, Gamble JM.   (2018). Patient preferences among individuals with type 2 diabetes for attributes of diabetes medications: A Discrete Choice Experiment. International Society of Pharmacoepidemiology, Toronto, Ontario, Canada. April, 2018.

 

9.      Grandy C, Donnan J, Peddle P, Romme K, Kim S, Gamble JM.(2018). A systematic Review of Clinical Drug Data for Building Knowledge Translation Products. Canadian Association of Pharmacy Students and Interns Professional Development Week

 

10.  Donnan J, Grandy C, Chibrikov  E, Marra C, Aubrey-Bassler K, Johnston K, Najafzadeh M, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. (2017). Comparative Safety of the Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Systematic Review and Meta-Analysis. Canadian Association for Population Therapeutics Annual Conference

 

11.  Gamble JM, Donnan J, Chibrikov E, Twells L, Midodzi W, Majumdar S. (2017). The Risk of Fragility Fractures in New Users of Dipeptidyl Peptidase-4 Inhibitors Compared to Sulfonylureas and Other Anti-Diabetic Drugs: A Cohort Study. Canadian Association for Population Therapeutics Annual Conference

 

12.  Donnan, J. (2017). Non-Industry Sources of Drug Information. Family Medicine Medical Ethics Workshop, St. John's, Canada

 

13.  Donnan, J (2017). Diabetes Management: Assessing Benefits, Risks and Patient Preferences. School of Pharmacy. Graduate Seminar Series, St. John's, Canada

 

14.   Donnan J, Marra C, Aubrey-Bassler K, Johnston K, Najafzadeh M, Swab M, Gamble JM. (2016). Incorporating Patient Preferences into a Quantitative Risk Benefit Analysis of Type 2 Diabetes Therapies: A Proposed Approach. TPMI Second Annual Research Day, St. John's, Canada

 

15.  Donnan J. (2016). Incorporating patient preferences into Benefit Risk Analysis: A Proposed Discrete Choice Experiment for Type 2 Diabetes Medications. Memorial University School of Pharmacy Graduate Seminar Series, St. John's, Canada

 

16.  Herd C, Norris P, Horsburgh S, Aaltonen K, Donnan J, Hawboldt J, Morgan S, Roughead E, Schafheutle E, Tamblyn R. (2016). What patients pay for medicines: A comparison of five countries. National Medicines Symposium, Canberra, Australia

 

17.  Donnan J. (2016). Benefit Risk Analysis: An introduction and Discussion of a Unified Framework. Memorial School of Pharmacy Graduate Seminar Series, St. John's, Canada

 

18.  Donnan J, Faseruk A, Cooper T (2014). An Examination of the Ethical Considerations for Orphan Drug Decision Frameworks. North American Management Society, MBAA International Conference, Chicago, United States

 

19.  Donnan J, Faseruk A. (2012). The Financial Implications of Using Decision Tree Analysis for Publicly Funded Health Care Screening in Canada. North American Management Society, MBAA International Conference, Chicago, United States

 

20.  Sikdar KC, Donnan J, MacDonald D. (2011). Adverse Drug Event Monitoring in Newfoundland and Labrador: Opportunities for Provincial Drug Information Systems. 2011 e-Health Conference, Toronto, Ontario, Canada. 

 

21.  J Donnan (2010). Cost-effectiveness analysis of thiopurine methyltransferase testing to guide mercaptopurine starting doses in pediatric patients with acute lymphoblastic leukemia. Canadian Association of Population Therapeutics, Toronto, Canada

 

22.  J Donnan (2009). Illegal use of Prescription Drugs prior to the implementation of a province-wide pharmacy network. The Canadian Association for Population Therapeutics Annual Conference, Montreal, Canada

 

23.  J Donnan (2009). Data-mining in the Pharmacy Network: Digging Deep to Improve Health Care. Pharmacists Association of Newfoundland and Labrador Annual General Meeting., Gander, Canada

 

24.   J Donnan (2009). Trends in the use of potentially harmful medications among seniors prior to the implementation of a pharmacy network. Canadian Association for Population Therapeutics Annual Conference, Montreal, Canada

 

25.  Sikdar KC, Alaghehbandan R, Donnan J, MacDonald D, Gadag V, Barrett B. (2008) Emergency Department visits in adult patients caused by Adverse Drug Events, Newfoundland and Labrador. Data Users Conference 2008: Linking the Health Information Chain, Ottawa, Canada

 

26.  Donnan J (2008). Validation of an Adverse Drug Event Trigger Assessment Tool. Canadian Society of Hospital Pharmacists, Annual General Meeting., Saint John, Canada

 

27.  Loder J, Lamoure J. (2006). Suspected Drug Interaction Between Clozapine and Clarithromycin Resulting in Prolonged Hospitalization. Canadian Society of Hospital Pharmacy Professional Practice Conference, Toronto, Canada

© 2020 by Jennifer Donnan